Osman YILMAZ, Tuğra GENÇPINAR, Çağatay BİLEN, Berke ÖZKAN, Baran UĞURLU, Bekir ERGÜR, Pınar AKOKAY

Tavşan karotis arter modelinde bemiparinin neointimal hiperplazi ve endotelyal hücre proliferasyonu üzerine etkisi

Amaç: Bu çalışmada bemiparinin neointimal hiperplazi ve endotelyal hücre proliferasyonu üzerine olan etkileri bir tavşan karotis arter modelinde araştırıldı.Çalışma planı: Mart 2015 - Nisan 2015 tarihleri arasında rastgele seçilen, 2 ila 3 kg ağırlığında 12 Yeni Zelanda tavşanı iki gruba ayrıldı. Sağ karotis arterler transekte edildi ve 8- 0 prolen, devamlı sütur tekniği ile sütüre edildi. Kontrol grubuna (n=6) herhangi bir ilaç verilmez iken, çalışma grubuna (n=6) yedi gün boyunca 150 IU/kg/gün bemiparin verildi. Tavşanların tümü 28. günde sakrifiye edildi ve karotis arter segmentleri çıkarılarak, histolojik inceleme için hazırlandı.Bulgular: Tüm histokimyasal ve histomorfolojik analizler gruplara kör iki araştırmacı tarafından yapıldı. Kontrol grubunun damar örneklerinin kesitsel analizinde, tunika intimada kalınlaşma izlendi ve bir kesitte intimal kalınlaşma çok az sayıda rekanalizasyon alanları ile birlikte lümeni neredeyse tamamen tıkamıştı. Bemiparin grubunda, kontrol grubuna kıyasla, intimal hiperplazi (p

The effect of bemiparin on neointimal hyperplasia and endothelial cell proliferation in a rabbit carotid artery model

Background: The aim of this study was to investigate the effects of bemiparin on neointimal hyperplasia and endothelial cell proliferation in a rabbit carotid artery model.Methods: Between March 2015 and April 2015 12 randomly-selected New Zealand male rabbits, weighing 2 to 3 kg, were divided into two groups. The right carotid arteries were transected and sutured with 8-0 polypropylene material with continuous suture technique. The control group (n=8) received no additional medication, while the study group (n=6) received 150 IU/kg/day of bemiparin for seven days. All rabbits were sacrificed on Day 28, and the carotid artery segments were removed and prepared for histological examination.Results: All histochemical and histomorphological analyses were performed by two investigators who were blind to the groups. In the cross-section analysis of the vessel specimens of the control group, thickening of the tunica intima was noticed, and in a section, the intimal thickening was almost occluding the lumen with a few recanalization areas. In the bemiparin group, the intimal hyperplasia (p

PDF

___

26. Dogan OT, Polat ZA, Karahan O, Epozturk K, Altun A, Akkurt I, et al. Antiangiogenic activities of bemiparin sodium, enoxaparin sodium, nadroparin calcium and tinzaparin sodium. Thromb Res 2011;128:29-32.
25. Katrancioglu N, Karahan O, Kilic AT, Altun A, Katrancioglu O, Polat ZA. Comparison of the antiangiogenic effects of heparin sodium, enoxaparin sodium, and tinzaparin sodium by using chorioallantoic membrane assay. Blood Coagul Fibrinolysis 2012;23:218-21.
24. Yavuz C, Caliskan A, Karahan O, Yazici S, Guclu O, Demirtas S, et al. Investigation of the antiangiogenic behaviors of rivaroxaban and low molecular weight heparins. Blood Coagul Fibrinolysis 2014;25:303-8.
23. Caliskan A, Yavuz C, Karahan O, Yazici S, Guclu O, Demirtas S, et al. Factor-Xa inhibitors protect against systemic oxidant damage induced by peripheral-ischemia reperfusion. J Thromb Thrombolysis 2014;37:464-8.
22. Fish JE, Marsden PA. Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium. Cell Mol Life Sci 2006;63:144-62.
21. Atiq F, van den Bemt PM, Leebeek FW, van Gelder T, Versmissen J. A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency. Eur J Clin Pharmacol 2015;71:921-9.
20. Kakkar VV, Howes J, Sharma V, Kadziola Z. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Thromb Haemost 2000;83:523-9.
19. Nenci GG, Minciotti A. Low molecular weight heparins for arterial thrombosis. Vasc Med 2000;5:251-8.
18. Williams MS, Ng’alla LS. Heparin therapy leads to platelet activation and prolongation of PFA-100 closure time. J Cardiovasc Pharmacol Ther 2005;10:273-80.
17. Chapman TM, Goa KL. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs 2003;63:2357-77.
16. Pérez-Ruiz A, Montes R, Carrasco P, Rocha E. Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium. Clin Appl Thromb Hemost 2002;8:65-71.
15. Ahmad SS, London FS, Walsh PN. The assembly of the factor X-activating complex on activated human platelets. J Thromb Haemost 2003;1:48-59.
14. Jeske WP, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, et al. A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Thromb Res 2011;128:361-7.
13. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188-203.
12. Planès A. Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism. Expert Opin Pharmacother 2003;4:1551-61.
11. Demirtas S, Karahan O, Yazıcı S, Guclu O, Calıskan A, Tezcan O, et al. Investigation of possible prophylactic, renoprotective, and cardioprotective effects of thromboprophylactic drugs against ischemia-reperfusion injury. Kaohsiung J Med Sci 2015;31:115-22.
10. Gencpınar P, Tüzün F, Ozbal S, Tuğyan K, Duman N, Ozkan H, et al. Effects of neotrofin on neonatal hypoxic ischemic brain injury. Neurosci Lett 2011;505:205-10.
9. Ergür BU, Çilaker Mıcılı S, Yılmaz O, Akokay P. The effects of -lipoic acid on aortic injury and hypertension in the rat remnant kidney (5/6 nephrectomy) model. Anatol J Cardiol 2015;15:443-9.
8. Li R, Lan B, Zhu T, Yang Y, Wang M, Ma C, et al. Establishment of an animal model of vascular restenosis with bilateral carotid artery grafting. Med Sci Monit 2014;20:2846-54.
7. Guzeloglu M, Aykut K, Albayrak G, Atmaca S, Oktar S, Bagriyanik A, et al. Effect of tadalafil on neointimal hyperplasia in a rabbit carotid artery anastomosis model. Ann Thorac Cardiovasc Surg 2013;19:468-74.
6. Lopez-Belmonte Encina E, Gutierro Aduriz I. Patent Application Publication US, 2012/0189698 A1. Available from: http://patentimages.storage.googleapis.com/pdfs/ US20120189698.pdf
5. Martínez-González J, Vila L, Rodríguez C. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism. Expert Rev Cardiovasc Ther 2008;6:793 -802.
4. Sánchez-Ferrer CF. Bemiparin: pharmacological profile. Drugs 2010;70:19-23.
3. Da Pozzo E, Barsotti MC, Bendinelli S, Martelli A, Calderone V, Balbarini A, et al. Differential effects of fondaparinux and bemiparin on angiogenic and vasculogenesis-like processes. Thromb Res 2012;130:113-22.
2. More RS, Rutty G, Underwood MJ, Brack MJ, Gershlick AH. A time sequence of vessel wall changes in an experimental model of angioplasty. J Pathol 1994;172:287-92.
1. Karaarslan K, Abud B, Albayrak G, Aykut K, Ergür BU, Silistreli E. The effect of resveratrol on intimal hyperplasia and endothelial proliferation of rabbit carotid artery anastomosis. Interact Cardiovasc Thorac Surg 2015;20:15-20.